Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

328 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-01

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

New coronavirus infection is an important cause of public health emergencies at home and abroad, which seriously affects people's health and social stability. The outbreak of SRAR-COV in China in 2003 caused serious social impact. From January 2002 to August 7, 2003, there were a total of 8,422 cases worldwide, involving 32 countries and regions, of which 919 cases were fatal, with a fatality rate of nearly 11%. The fatality rate of elderly patients and patients with underlying diseases was even more high.There is no precise and effective treatment for coronavirus infection. In vitro, IFN-α2β has inhibitory effects on MERS-CoV and closely related coronavirus severe acute respiratory syndrome (SARS) -CoV. A study showed the effects of interferon-α2β and ribavirin on the replication of nCoV isolates hCoV-EMC / 2012 in Vero and LLC-MK2 cells. The combined application may be useful for the management of patients with nCoV infection in the future. At present, the combination therapy of interferon α2β and ribavirin has been successfully applied in the initial treatment and prevention of SARS and MERS.The purpose of this study was to evaluate the efficacy and safety of recombinant human interferon α1β in treating patients with new coronavirus infection in Wuhan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

NCT04320238

2019 Novel Coronavirus Infection

UNKNOWN PHASE3

Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients

NCT04449380

COVID-19 Virus Infection

TERMINATED PHASE2

Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza

NCT01227798

Influenza

UNKNOWN PHASE1/PHASE2

A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants

NCT05257798

Healthy

COMPLETED PHASE1

Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

NCT04480138

Covid19

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multi-center, randomized, open, blank-controlled, multi-stage clinical study. As there are no effective treatments, the project team will evaluate possible treatments (including but not limited to interferon α) based on actual conditions. , Lopinavir / ritonavir, remdesivir, single / polyclonal antibodies against coronavirus), explore the most effective antiviral treatment options.

The first phase will assess the efficacy and safety of interferon alpha compared to standard treatment for approximately 328 hospitalized adult patients diagnosed with a new coronavirus infection in Wuhan.

Patients with COVID-19 within 7 days of onset of symptoms were screened and randomly assigned as soon as possible after screening (within 24 hours). Patients will be allocated in a 1: 1 ratio, receiving the interferon alpha treatment group or only the standard treatment group. Patients who do not meet the inclusion and exclusion criteria are only allowed to be re-screened once, provided that the time from symptom onset to randomization remains within 7 days.

This study planned to randomize approximately 328 adult subjects. It will be stratified according to whether the onset time is ≤ 3 days, and randomly divided into groups of 1: 1, receiving standard treatment or interferon alpha atomization twice a day, 1 stick (10ug) each time, treatment course For 10 days. Subjects and all research center staff were not blinded.

The primary endpoint of this study was the incidence of side effects within 14 days of enrollment. Therefore, a 14-day visit is essential for the data needed for this endpoint. Every effort should be made to ensure that this study visit is completed in a timely manner.

Out-of-hospital treatment or discharge will reach the discharge standard on the day of implementation and will be implemented in accordance with the Health and Medical Commission's "Unknown Viral Pneumonia Diagnosis and Treatment Plan (Trial)". For patients treated outside the hospital or who have been discharged, final assessments are performed by phone and using a questionnaire (if applicable).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Recombinant Human Interferon α1β

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard therapy + interferon therapy

Standard treatment + recombinant human interferon α1β 10ug Bid was administered by nebulization for 10 days.

Group Type EXPERIMENTAL

Recombinant human interferon α1β

Intervention Type DRUG

Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation

Standard therapy + blank therapy

Standard therapy

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recombinant human interferon α1β

Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years;
2. Clinically diagnosed patients with new type of coronavirus pneumonia, including: in accordance with the criteria for suspected cases, have one of the following etiology evidence:

① Real-time fluorescence RT-PCR of respiratory specimens or blood specimens for detection of new coronavirus nucleic acid;

② Sequencing of viral genes in respiratory specimens or blood specimens, highly homologous to known new coronavirus
3. The time interval between the onset of symptoms and random enrollment is within 7 days. The onset of symptoms is mainly based on fever. If there is no fever, cough, diarrhea or other related symptoms can be used.

Exclusion Criteria

1. Any situation where the programme cannot be carried out safely;
2. Patients who have used interferon or remedesivir;
3. No clinical manifestations and chest imaging findings
4. Known allergy or hypersensitivity to interferon (including asthma);
5. Disabled in patients with uncontrolled autoimmune diseases;
6. Patients with severe heart disease, decompensated liver disease, renal insufficiency (CrCL \<50ml / min), and those with abnormal bone marrow function are prohibited;
7. Epilepsy and impaired central nervous system function;
8. Pregnancy: Positive pregnancy test for women of childbearing age;
9. Breastfeeding women have not stopped breastfeeding;
10. The patient may be transferred to a non-participating hospital within 72 hours.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No